Fusion Antibodies make key Covid-19 Reagents available

As part of our efforts to combat the Covid-19 pandemic, Fusion Antibodies have designed and expressed a panel of unique recombinant protein antigens for use in our new Fully Human Antibody Library platform and other discovery platforms in the search for a neutralising therapeutic antibody against SARS-CoV 2.  ​

The panel of proteins incorporate a unique RBD construct, as well as S1 and full spike ectodomain proteins incorporating the D614G mutation, and have shown excellent profiles in terms of activity and scalability.  ​

We are conscious that the fight against Covid-19 is a worldwide effort and as such we are happy to announce our decision to make these proteins available to our partners in the diagnostic field.